Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Drosten

Showing results (1-10 of 46) with videos related to

Pageof 5
Sort By:
Molecular Oncology|December 24, 2021
Targeting KRAS mutant lung cancer: light at the end of the tunnelMatthias Drosten, Mariano Barbacid
Molecular Oncology|November 16, 2022
KRAS inhibitors: going noncovalentMatthias Drosten, Mariano Barbacid
Cancer Cell|April 15, 2020
Targeting the MAPK Pathway in KRAS-Driven TumorsMatthias Drosten, Mariano Barbacid
Trends in Cancer|June 12, 2024
A new BRAF inhibitor breaks resistance barriersMorena Scotece, Matthias Drosten
Molecular & Cellular Oncology|June 17, 2016
Ras and p53: An unsuspected liaisonMatthias Drosten, Mariano Barbacid
Journal of Molecular Medicine (Berlin, Germany)|November 4, 2015
Modeling K-Ras-driven lung adenocarcinoma in mice: preclinical validation of therapeutic targetsMatthias Drosten, Mariano Barbacid
Molecular Oncology|October 29, 2025
The rapidly growing landscape of RAS inhibitors: from selective allele blockade to broad inhibition strategiesMatthias Drosten, Mariano Barbacid
Journal of Molecular Medicine (Berlin, Germany)|June 18, 2003
Gene therapeutic approaches for medullary thyroid carcinoma treatmentMatthias Drosten, Brigitte M Pützer
Nature Clinical Practice. Oncology|October 5, 2006
Mechanisms of Disease: cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapyMatthias Drosten, Brigitte M Pützer
Trends in Molecular Medicine|July 10, 2004
The RET proto-oncogene: a potential target for molecular cancer therapyBrigitte M Pützer, Matthias Drosten
Pageof 5

Showing results (1-10 of 46) with videos related to

Sort By:
Pageof 5
Molecular Oncology|December 24, 2021
Targeting KRAS mutant lung cancer: light at the end of the tunnelMatthias Drosten, Mariano Barbacid
Molecular Oncology|November 16, 2022
KRAS inhibitors: going noncovalentMatthias Drosten, Mariano Barbacid
Cancer Cell|April 15, 2020
Targeting the MAPK Pathway in KRAS-Driven TumorsMatthias Drosten, Mariano Barbacid
Trends in Cancer|June 12, 2024
A new BRAF inhibitor breaks resistance barriersMorena Scotece, Matthias Drosten
Molecular & Cellular Oncology|June 17, 2016
Ras and p53: An unsuspected liaisonMatthias Drosten, Mariano Barbacid
Journal of Molecular Medicine (Berlin, Germany)|November 4, 2015
Modeling K-Ras-driven lung adenocarcinoma in mice: preclinical validation of therapeutic targetsMatthias Drosten, Mariano Barbacid
Molecular Oncology|October 29, 2025
The rapidly growing landscape of RAS inhibitors: from selective allele blockade to broad inhibition strategiesMatthias Drosten, Mariano Barbacid
Journal of Molecular Medicine (Berlin, Germany)|June 18, 2003
Gene therapeutic approaches for medullary thyroid carcinoma treatmentMatthias Drosten, Brigitte M Pützer
Nature Clinical Practice. Oncology|October 5, 2006
Mechanisms of Disease: cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapyMatthias Drosten, Brigitte M Pützer
Trends in Molecular Medicine|July 10, 2004
The RET proto-oncogene: a potential target for molecular cancer therapyBrigitte M Pützer, Matthias Drosten
Pageof 5